We are a preclinical stage company developing a safer epigenetic gene therapies. The lead program targets SCN9A (Nav1.7) for chronic pain (GMP manufature started). We also have Nav1.8 and dual 1.7+1.8 targeting leads. Finally, one ophthalmology program and one rheumatoid arthritis program.